PET/CT imaging with radiolabeled monoclonal antibodies and EGFR TKIs is particularly attractive and may be better than 18F-FDG PET/CT-derived radiomics in detecting EGFR mutation status in NSCLC because it can be repeatedly operate and reflect receptor status in real-time. This evidence concerns the gene EGFR and non-small cell lung carcinoma.